The αeolus, developed in a collaboration between Kindeva Drug Delivery and Cambridge Healthcare Innovations, is a passive, high-performance, high-consistency dry powder inhaler (DPI) platform concept. This technology has produced promising preliminary results, addressing common concerns with passive DPIs through innovative engineering and novel technologies. Download this article to delve into the performance of the αeolus and the benefits of this platform.  

Back to Resources

Combine Forces With Kindeva